Author

Tian Feng

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY

Edward V. Loftus, Jean-Frédéric Colombel, Ana Paula Lacerda, Laurent Peyrin-Biroulet, Geert R. D'Haens, Remo Panaccione, Walter Reinisch, Edouard Louis, Minhu Chen, Hiroshi Nakase, Susan Greenbloom, Aaron Duvall, Yuri Sanchez Gonzalez, Mohamed-Eslam F. Mohamed, Susan Rhee, Tian Feng, Elena Dubcenco, Julian Panés

Item 1 - 2 / 2
1